An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.

• Main Authors: Eva Iniguez (Author), Nathaniel S Schocker (Author), Krishanthi Subramaniam (Author), Susana Portillo (Author), Alba L Montoya (Author), Waleed S Al-Salem (Author), Caresse L Torres (Author), Felipe Rodriguez (Author), Otacilio C Moreira (Author), Alvaro Acosta-Serrano (Author), Katja Michael (Author), Igor C Almeida (Author), Rosa A Maldonado (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2017-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Protozoan parasites from the genus Leishmania cause broad clinical manifestations known as leishmaniases, which affect millions of people worldwide. Cutaneous leishmaniasis (CL), caused by L. major, is one the most common forms of the disease in the Old World. There is no preventive or therapeutic h...